Neoadjuvant treatment for rectal cancer-A value-based proposition.
Over the last decade, the use of neoadjuvant chemo-radiation has been an integral part of the care of patients with locally advanced rectal cancer. However, emerging data are beginning to challenge the current treatment paradigm of neoadjuvant chemo-radiation followed by radical resection and subsequent adjuvant chemotherapy. Going forward, the challenge will be to identify patients for whom radiation can be safely omitted and those for whom it can potentially provide added oncologic value. J. Surg. Oncol. 2016;114:304-310. © 2016 Wiley Periodicals, Inc.
VA Health Services Research and Development Center for Innovations in Quality, Effectiveness and Safety, Michael E DeBakey VA Medical Center, Houston, Texas.|Division of Surgical Oncology, Michael E DeBakey Department of Surgery, Baylor College of Medicine, Houston, Texas.
Nader N
NN
Massarweh
Division of Surgical Oncology, Michael E DeBakey Department of Surgery, Baylor College of Medicine, Houston, Texas.
Avo
A
Artinyan
Departments of Surgical Oncology and Health Services Research, The University of Texas MD Anderson Cancer Center Houston, Houston, Texas.
George J
GJ
Chang
D059248:Chemoradiotherapy; D003362:Cost-Benefit Analysis; D006801:Humans; D020360:Neoadjuvant Therapy; D012004:Rectal Neoplasms / Q000401:mortality / Q000473:pathology / Q000628:therapy*; D062505:Value-Based Purchasing
neoadjuvant; radiation; rectal cancer; value